# Open-Label Study of Vaginal AZU-101 in Postmenopausal Women

> **NCT06197568** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Azure Biotech Inc.** · enrollment: 35 (estimated)

## Conditions studied

- Postmenopausal Symptoms

## Interventions

- **DRUG:** Lasofoxifene Tartrate (AZU-101)
- **DRUG:** Lasofoxifene Tartrate (AZU-101)
- **DRUG:** Lasofoxifene Tartrate (AZU-101)
- **DRUG:** Lasofoxifene Tartrate (AZU-101)
- **DRUG:** Lasofoxifene Tartrate (AZU-101)

## Key facts

- **NCT ID:** NCT06197568
- **Lead sponsor:** Azure Biotech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06197568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06197568, "Open-Label Study of Vaginal AZU-101 in Postmenopausal Women". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06197568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*